Debra A. Goff, Pharm.D., FCCP

Debra A. Goff, PharmD, FCCP, is an Infectious Disease Specialist and past Program Director of the Infectious Diseases Residency at The Ohio State University Wexner Medical Center (OSUWMC) in Columbus, Ohio. Dr. Goff is a founding member of the Antimicrobial Stewardship Program (ASP) and leads the research program for the Department of Pharmacy. Dr. Goff received her bachelor of pharmacy degree, Doctor of Pharmacy degree, and performed her Pharmacy residency at the University of Illinois at Chicago.

She is a faculty member of the ASHP National Antimicrobial Stewardship mentoring program that provides on-site mentoring to help clinicians learn how to achieve excellence in their ASP. She is also a faculty member and international advisor to the Federation of Infectious Diseases Society of South Africa (FIDSSA) educating and mentoring South African health care providers about stewardship. She is the 2014-2016 recipient of an OSU Outreach and Engagement grant to provide training and mentoring to South African pharmacists. She also is involved in the national research initiative with Making a Difference Infectious Diseases (MAD-ID).

She is actively involved in developing strategies to improve patient outcomes and control the escalating rate of antimicrobial resistance. Dr. Goff incorporates new technology to create useful tools to educate health care providers. She developed a web-based “app” for OSUWMC called STAB-IT (Staphylococcus aureus bacteremia – is terrible) to help guide clinicians on the management of patients with S. aureus bacteremia. She developed and co-authored 2 apps in the Apple & Google Store called Management of Candidemia and Management of Invasive Aspergillosis and Rare Molds in a Stewardship Era. She published an iBook for the iPad titled “Infectious Diseases: There’s an App for That” to provide a free global educational tool for stewardship programs worldwide.

She teaches a social media workshop for healthcare providers titled “How to Use Twitter for Antimicrobial Stewardship”. She is currently studying “Engaging Surgeons in Antimicrobial Stewardship Using Twitter”. She has received numerous research grants and lectures both nationally and internationally. She has published in several journals, including Clinical Infectious Diseases, Archives of Internal Medicine, Antimicrobial Agents and Chemotherapy, Pharmacotherapy, and othersHer research interest includes antimicrobial resistance, application of rapid diagnostic tests, clinical outcomes, and innovative ways to educate using technology. She is an active member of IDSA, ACCP, ASM, SIDP, MAD-ID and a board member of the National Foundation for Infectious Diseases (NFID) and MAD-ID.

Attila Lorincz, Ph.D.

Dr. Lorincz received a doctorate in genetics from Trinity College, University of Dublin, Ireland. While a research fellow at the University of California, Santa Barbara, he was the first to report that yeast cdc28 is a protein kinase and the prototype of the human cell cycle cdk genes. His human papillomavirus studies began in collaboration with Nobel Laureate Harald zurHausen and this work produced clones of many novel carcinogenic HPV types. In 1990, Dr. Lorincz co-founded Digene Corp. (now QIAGEN Inc.) as Chief Scientific Officer. His research led to the Hybrid Capture (HC) series of tests. HC2 was the first HPV test to be FDA-approved for cervical pre-cancer screening and is widely regarded as the international reference standard. His subsequent research work includes the development of a simple robust HPV test for resource-limited regions and a randomized clinical trial to validate self-sampling as an efficient screening approach to prevent cervical cancer.

Dr. Lorincz is Director of the Molecular Epidemiology Laboratory at the Wolfson Institute of Preventive Medicine where his research interests include the epigenomics of prostate, breast and cervical cancers. Recently his team has developed a set of new diagnostic and prognostic cancer biomarkers based on DNA methylation assays. He is leading a new discovery initiative in next-generation deep sequencing and in elucidating the comparative epigenomic systems of human cancers. Dr. Lorincz has written more than 240 peer-reviewed papers and is an inventor on 45 patents related to diagnostic and prognostic testing. He was the recipient of several prestigious prizes including the 1994 American Venereal Disease Association Achievement Award and THE TIMES Award 2012 for UK research project of the year. Currently he serves as the Editor-in-Chief of Expert Reviews in Molecular Diagnostics.

Stefan Riedel, M.D., Ph.D., D(ABMM), FCAP

Dr. Riedel is the Associate Medical Director of the Clinical Microbiology Laboratories at Beth Israel Deaconess Medical Center in Boston, MA, and he holds the academic rank of Associate Professor of Pathology at Harvard Medical School. From 2007 to 2016, Dr. Riedel was the Director of the Clinical Pathology Laboratories at Johns Hopkins Bayview Medical Center, with concomitant appointments as Assistant Professor of Pathology (2007-2014) and Associate Professor of Pathology (2014-2016) at The Johns Hopkins University, School of Medicine. From 2015-2016, he also held a secondary appointment as Associate Professor of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health. He currently maintains appointments as an Adjunct Associate Professor of Pathology and Medicine at The Johns Hopkins University, School of Medicine.

Dr. Riedel’s research is focused on the diagnosis and management of sepsis as well as emerging antimicrobial resistance in gram-negative bacteria, including Neisseria gonorrhoeae, Enterobacteriacea, and non-fermentative bacteria such as Acinetobacter and Pseudomonas. He is particularly interested in surveillance programs for antimicrobial resistance, to enhance the understanding of emergence of antimicrobial resistance as well as the development of interventions to decrease the spread of resistance.

Dr. Riedel is a member of the following professional organizations: American Society for Microbiology (ASM), College of American Pathologists (CAP), and the American Society for Clinical Pathology (ASCP). He serves as a member of the CAP Microbiology Resource Committee, the Federal Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA), and as an advisor to the National Antimicrobial Susceptibility Testing Committee for the United States (USCAST). In addition, he serves as an associate editor for BMC Infectious Diseases and is member of the editorial board of the Journal of Clinical Microbiology.

Dr. Riedel received his M.D. and Ph.D. degrees in 1996 and 1999, respectively, from the Johann Wolfgang Goethe University in Frankfurt, Germany. After initial clinical training in general and orthopaedic surgery in England, Germany, and Switzerland, he completed residency training in anatomic and clinical pathology at Baylor University Medical Center in Dallas, TX, and a 2-year fellowship in medical and public health microbiology at the University of Iowa Hospitals & Clinics in Iowa City, IA. Dr. Riedel is board certified in Clinical Pathology and Medical Microbiology by the American Board of Pathology, and is a diplomate (active status) of the American Board of Medical Microbiology (ABMM).

Patricia (Trish) Simner, Ph.D., D(ABMM)

Dr. Simner is an Associate Professor of Pathology at the Johns Hopkins University School of Medicine and the Director of the Medical Bacteriology and Parasitology Laboratories at the Johns Hopkins Medical Institutions. She completed her undergraduate and graduate studies at the University of Manitoba in Manitoba, Canada and a two year Clinical Microbiology Fellowship at the Mayo Clinic in Rochester, MN.  Her research has focused on understanding the epidemiology and molecular mechanisms of resistance of Gram-negative bacteria, in particular those harboring β-lactamase enzymes. With the increasing prevalence of carbapenemase-producing organism (CPO), her focus has evolved to studying novel diagnostic methods for the detection of these clinically important pathogens and understanding their mechanisms of resistance and spread in the hospital setting.  She is well published with greater than 65 peer-reviewed manuscripts and 10 book chapters.

Dr. Simner is currently the principal investigator for a National Institute of Health (NIH) grant which seeks to understand the molecular mechanisms of antibiotic resistance and spread amongst all CPO in a region of the US endemic for CPO.  In addition, she is involved in many interdisciplinary collaborative research projects.  She is also interested in novel diagnostic tools for infectious diseases and is actively involved in validating metagenomic next-generation sequencing as a diagnostic tool.

Dr. Simner is an advisor for the Subcommittee on Antimicrobial Susceptibility Testing for the Clinical and Laboratory Standards Institute, a member of the Antimicrobial Resistance Surveillance Taskforce for the CDC and she was recently elected as the Early Career At-Large representative for the American Society for Microbiology (ASM) Council on Microbial Sciences.  She is also an Editorial Board Member for the Journal of Clinical Microbiology.

Finally, Dr. Simner was selected as the recipient of the 2018 ASM Diagnostic Young Investigators’ Award and was recognized as the 2018 Department of Microbiology Distinguished Alumna from the University of Manitoba, Canada.

James W. Snyder, Ph.D., D(ABMM), FAAM

Dr. Snyder is the Medical Director of the Clinical Microbiology and Molecular Diagnostics Laboratory at the University of Louisville Hospital, and holds the academic rank, Professor of Pathology and Laboratory Medicine, at the University of Louisville School of Medicine.

He holds active memberships in the following professional organizations: American Society for Microbiology, South Central Association for Clinical Microbiology, Infectious Disease Society of America, Pan American Virology Association, Society of Surgical Infections, and The Medical Mycological Society of America.

He serves the American Society for Microbiology as its representative to the Laboratory Response Network (LRN) for Preparedness and Response to Bioterrorism and Emerging Infectious Diseases, coordinating editor of the LRN Sentinel Level Laboratory Testing Protocols, co-author of the Anthrax Sentinel Level Protocol, a member of the Laboratory Practices Committee, coordinating editor of the Clinical Microbiology Procedures Handbook, former chairman of Division C (Clinical Microbiology) of the ASM, and a reviewer for the Journal of Clinical Microbiology. He recently was selected to represent the ASM on the APHL Biosafety and Biosecurity Committee. He is a lifetime member of the South Central Association of Clinical Microbiology (SCACM) and has held several leadership positions including having been elected twice as President, and currently serves as a member of the program planning committee for the SCACM Audioconference Series. He has authored or co- authored over 60 publications, five book chapters, numerous abstracts, research posters, and presented numerous invited presentations at the regional, national, and international levels.

Dr. Snyder received his BS and MS degrees from Eastern Kentucky University, his doctorate from the University of Dayton, is board certified as a Diplomat of the American Board of Medical Microbiology, and is a Fellow in the American Academy of Microbiology.

He retired from the U.S. Army Reserves with over 43 years of service including deployment to Iraq in 2011 where he commanded the Medical Task Force in support of Operation New Dawn.

Jorge Leon, Ph.D.

Dr. Leon is an Immunologist and Molecular Biologist with vast experience in developing, establishing a vision and managing Clinical Immunology and Molecular Diagnostics Laboratories, including the largest Molecular Diagnostics Lab in the world, with $1.5 billion in revenues today.

He received his doctorate in Immunology from Andes University in Bogota Colombia and then completed postdoctoral research at the German Cancer Center in Heidelberg.  Additionally, he received a doctorate in Cellular and Molecular Biology from New York University and completed postdoctoral research at Columbia University.  His research interest has been breast cancer, where at Columbia University he contributed with the creation of the first generation of monoclonal antibodies against Breast Cancer associated antigens.  His research has included the characterization of the MUC-1 protein and the development of the first serum immunoassay for helping in the detection of recurrences in breast cancer and applications for circulating tumor cells and radio immunoimaging in the clinical field.

Later, during his tenure at Quest Diagnostics, Dr. Leon actively participated in the clinical validation and implementation of multiple prognostic, predictive and companion diagnostic tests for breast and other cancers.

As the founder of a specialized advising firm in Molecular Diagnostics and Personalized Medicine, Dr. Leon has been a senior advisor for several entities where he played a critical in the inception, development and implementation of breakthrough technologies for seminal companies in the fields of Clinical oncology and Genetic testing.  Among those are Sequenom’s Mass Array and Pre-natal NGS , Solexa’s massive parallel sequencing, CTC’s companies Adnagen, Epic and Bio-site, Expression Signatures companies Genomic Health and Xdx,  Agendia’s Clinical Transcriptome tests and  Foundation Medicine’s NGS tumor panels. He has also helped build the Companion Diagnostics Strategies at DE biopharma, Novartis, Abbott, GE, Eli Lilly and the Gates Foundation among many more.

Dr Leon’s role as a senior advisor has also allow him to help the molecular diagnostics or immunology Labs and business of highly reputable academic institutions like Mayo Reference Labs (2004 to 2009), OHSU and the Knight Cancer Institute Mdx lab (2013-2018) and the Advanced Diagnostics Lab of National Jewish Health ( 2006-present).

One of the major focus of his work today is securing the reimbursement of effective novel tests, raising funds to develop new ideas (he has raised over $300M for start ups and academic centers) and making important molecular diagnostics tests accessible to global communities with low resources.